Shane Eleniak - Sep 25, 2021 Form 3 Insider Report for CALIX, INC (CALX)

Role
EVP, Products
Signature
/s/ Tom Gemetti as Attorney-in-fact for Shane Eleniak
Stock symbol
CALX
Transactions as of
Sep 25, 2021
Transactions value $
$0
Form type
3
Date filed
10/4/2021, 06:18 PM
Next filing
Oct 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CALX Stock Option (right to buy) Sep 25, 2021 Common Stock 90K $6.95 Direct F1
holding CALX Stock Option (right to buy) Sep 25, 2021 Common Stock 126K $5.95 Direct F2
holding CALX Stock Option (right to buy) Sep 25, 2021 Common Stock 50K $7.00 Direct F3
holding CALX Stock Option (right to buy) Sep 25, 2021 Common Stock 48K $8.03 Direct F4
holding CALX Stock Option (right to buy) Sep 25, 2021 Common Stock 200K $9.16 Direct F5
holding CALX Stock Option (right to buy) Sep 25, 2021 Common Stock 50K $9.16 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option grant are fully vested and exercisable.
F2 100% of the shares subject to the option grant are fully vested and exercisable.
F3 On August 1, 2018, the reporting person was awarded a nonqualified stock option grant covering 50,000 shares of common stock. 25% of the shares subject to the stock option grant vested on August 1, 2019, with the remainder having vested quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of September 25, 2021, 37,500 shares subject to the option grant are fully vested and exercisable.
F4 On February 14, 2019, the reporting person was awarded a performance-based nonqualified stock option grant covering 160,000 shares of common stock. On February 13, 2020, the Compensation Committee of Calix, Inc. determined that the performance criteria governing 30% of the grant had been achieved. Each nonqualified stock option award shall vest: (i) as to 25% of the shares of common stock subject to the stock option award, on February 13, 2020; and (ii) as to the remaining 75% of the shares of common stock subject to the stock option award, quarterly in equal installments over 36 months from February 13, 2020. As of September 25, 2021, 30,000 shares subject to the option grant are fully vested and exercisable.
F5 On January 31, 2020, the reporting person was awarded a performance-based nonqualified stock option grant covering 200,000 shares of common stock. On February 13, 2021, the Compensation Committee of Calix, Inc. determined that the performance criteria governing the grant had been achieved. Each nonqualified stock option award shall vest: (i) as to 25% of the shares of common stock subject to the stock option award, on January 31, 2021; and (ii) as to the remaining 75% of the shares of common stock subject to the stock option award, quarterly in equal installments over 36 months from January 31, 2021. As of September 25, 2021, 75,000 shares subject to the option grant are fully vested and exercisable.
F6 25% of the shares subject to the stock option grant vested on January 31, 2021, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of September 25, 2021, 18,750 shares subject to the option grant are fully vested and exercisable.